SEC 13F Intelligence

Managers / Q1 2026

Artal Group S.A.

CIK 0001053906 · VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, N4, L-2661 · (352) 22.42.59-1

Reported Value
$1.0B
Q1 2026
Positions
2
Filings on Record
31
2019–present window
Filed
May 14, 2026
original filing

Summary

Artal Group S.A. reported $1.0B in U.S.-listed holdings across 2 positions for Q1 2026.

The portfolio is heavily concentrated: CAVA alone accounts for 76.1% of reported value.

The book was largely unchanged from Q4 2025.

Portfolio Metrics

Turnover
0.0%
vs prior filed quarter
Largest Position
+76.1%
Cava

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $2.7BQ4 ’18Q1 ’19: $2.4BQ2 ’19: $2.5BQ3 ’19: $2.5BQ4 ’19: $2.6BQ4 ’19Q1 ’20: $2.4BQ2 ’20: $3.6BQ3 ’20: $4.1BQ4 ’20: $4.7BQ4 ’20Q1 ’21: $5.7BQ2 ’21: $4.9BQ3 ’21: $4.5BQ4 ’21: $3.7BQ4 ’21Q1 ’22: $2.4BQ2 ’22: $1.9BQ3 ’22: $2.3BQ1 ’23: $2MQ1 ’23Q2 ’23: $3MQ3 ’23: $2MQ4 ’23: $3MQ2 ’24: $3.9BQ2 ’24Q3 ’24: $2.4BQ4 ’24: $1.2BQ1 ’25: $884MQ2 ’25: $930MQ2 ’25Q3 ’25: $758MQ4 ’25: $715MQ1 ’26: $1.0Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 100.0%
  • Common Stock · 100.0% · $1.0B

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
LXRXLexicon Pharmaceuticals IncADDED+18.55M154.73M+$85M$241M
CAVACava Group IncHELD+09.51M+$211M$769M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

2 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CAVACava Group Inchistory →COM76.11%$769M9.51M
2LXRXLexicon Pharmaceuticals Inchistory →COM NEW23.89%$241M154.73M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.0B2May 14, 202613F-HRchanges · EDGAR ↗
Q4 2025$715M2Feb 12, 202613F-HRchanges · EDGAR ↗
Q3 2025$758M2Nov 12, 202513F-HRchanges · EDGAR ↗
Q2 2025$930M2Aug 13, 202513F-HRchanges · EDGAR ↗
Q1 2025$884M2May 14, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.2B2Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.4B2Nov 13, 202413F-HRchanges · EDGAR ↗
Q2 2024$3.9B114Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024Under review113May 17, 2024RESTATEMENTchanges · EDGAR ↗
Q4 2023$3M98Feb 9, 202413F-HRchanges · EDGAR ↗
Q3 2023$2M105Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$3M119Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$2M120May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review131Feb 13, 202313F-HRchanges · EDGAR ↗
Q3 2022$2.3B137Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.9B137Aug 11, 202213F-HRchanges · EDGAR ↗
Q1 2022$2.4B139May 12, 202213F-HRchanges · EDGAR ↗
Q4 2021$3.7B152Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$4.5B148Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$4.9B146Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$5.7B148May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$4.7B132Feb 11, 202113F-HRchanges · EDGAR ↗
Q3 2020$4.1B137Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$3.6B134Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$2.4B105May 14, 202013F-HRchanges · EDGAR ↗
Q4 2019$2.6B99Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$2.5B109Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$2.5B109Aug 9, 201913F-HRchanges · EDGAR ↗
Q1 2019$2.4B110May 10, 201913F-HRchanges · EDGAR ↗
Q4 2018$2.7B108Feb 11, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 5 additional managers.

  • Stichting Administratiekantoor Westend028-15028
  • Westend S.A.028-15029
  • Artal International Management S.A.028-15031
  • Artal International S.C.A.028-15033
  • Artal Participations S.a r.l.028-25146

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.